Anestesia Venosa Total (AVT) em Lactente com Doença de Werdnig-Hoffmann. Relato de Caso * Total Intravenous Anesthesia (TIVA) in an Infant with Werdnig-Hoffmann Disease. Case Report

SUMMARY Resende MAC, Silva EV, Nascimento OJM, Gemal AE, Quintanilha G, Vasconcelos EM – Total Intravenous Anesthesia (TIVA) in an In-fant with Werdnig-Hoffmann Disease. Case Report. BACKGROUND AND OBJECTIVES: Werdnig-Hoffmann disease is the most common cause of hypotonia in infants and its prognosis is worse if it is present shortly after delivery. Symmetrical muscular weakness, areflexia, and fasciculations of the tongue are character-istic. The majority of the infants die before two years of age as a con-sequence of respiratory failure. The present report presents a case in which total intravenous anesthesia was used. CASE REPORT: This is a 1 year old white female weighing 10 kg, physical status ASA III, with Werdnig-Hoffmann disease diagnosed at two months of age. The patient was a candidate for open gas-trostomy, fundus gastroplication, and tracheostomy. After venoclysis, the patient was monitored with cardioscope, non-invasive blood pres-sure, pulse oximeter, precordial stethoscope, and rectal temperature. She was oxygenated and, after bolus administration of atropine (0.3 mg), boluses of remifentanil (20 µg) and propofol (30 mg) were ad-ministered for anesthetic induction. After tracheal intubation, she was ventilated with manual controlled system without CO

[1]  J. Lerman,et al.  Inhalational anesthesia vs total intravenous anesthesia (TIVA) for pediatric anesthesia , 2009, Paediatric anaesthesia.

[2]  I. Snoeck,et al.  Survival in SMA type I: A prospective analysis of 34 consecutive cases , 2008, Neuromuscular Disorders.

[3]  T. Prior Spinal Muscular Atrophy Diagnostics , 2007, Journal of child neurology.

[4]  Fernando Squeff Nora,et al.  Remifentanil: ¿el régimen de infusión es la diferencia en la prevención de las respuestas circulatorias a la intubación traqueal? , 2007 .

[5]  I. Barker,et al.  A comparison of intubating conditions in children following induction of anaesthesia with propofol and suxamethonium or propofol and remifentanil , 2007, Anaesthesia.

[6]  Petra Kaufmann,et al.  Learning to walk , 2007, Neurology.

[7]  R. Flick,et al.  The risk of malignant hyperthermia in children undergoing muscle biopsy for suspected neuromuscular disorder , 2007, Paediatric anaesthesia.

[8]  H. Muñoz,et al.  Remifentanil Requirements During Propofol Administration to Block the Somatic Response to Skin Incision in Children and Adults , 2007, Anesthesia and analgesia.

[9]  D. Wysowski,et al.  Reports of Death with Use of Propofol (Diprivan) for Nonprocedural (Long-term) Sedation and Literature Review , 2006, Anesthesiology.

[10]  A. Simonds,et al.  Infantile cortical hyperostosis , 2005, Archives of Disease in Childhood.

[11]  M. Crawford,et al.  Dose-Response of Remifentanil for Tracheal Intubation in Infants , 2005, Anesthesia and analgesia.

[12]  V. Wong,et al.  Spinal Muscular Atrophy: Survival Pattern and Functional Status , 2004, Pediatrics.

[13]  D. Packer,et al.  Metabolic acidosis associated with propofol in the absence of other causative factors. , 2004, Anesthesiology.

[14]  A. Wolf,et al.  Propofol infusion in children: when does an anesthetic tool become an intensive care liability? , 2004, Paediatric anaesthesia.

[15]  M. I. Qureshi,et al.  Assessment of tracheal intubating conditions in children using remifentanil and propofol without muscle relaxant , 2004, Paediatric anaesthesia.

[16]  R. Videira,et al.  Remifentanil na prática clínica , 2004 .

[17]  R. Truog,et al.  Spinal muscular atrophy–type I , 2003, Archives of disease in childhood.

[18]  E. Erhan,et al.  Propofol — not thiopental or etomidate — with remifentanil provides adequate intubating conditions in the absence of neuromuscular blockade , 2003, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[19]  F. Kretz The future of paediatric anaesthesia is total intravenous anaesthesia. , 2002, Current opinion in anaesthesiology.

[20]  A. Munnich,et al.  Large scale deletions of the 5q13 region are specific to Werdnig-Hoffmann disease. , 1996, Journal of medical genetics.